With today's announcement of Roche buying ITMN, and Merck's recent acquisition of IDIX, one could speculate that VRTX could be a potential acquisition target for a large pharms looking for a ready to market growth franchise like it's CF drugs.
Pfizer/Fold Rx, Sanofi/Genzyme, Abbvie/Galapagos, and Gilead all have active research programs in CF which are years behind Vertex, and all with a need to bolster their pipeline with ready to market breakthrough drugs. I suspect Wall Street analyst speculation on the next big takeover will be mentioning VRTX as a potential target once again on Monday.
I thought I separated compound 31 and stem cell research in a separate paragraph. Stem cell research is a big plus for VRTX in my opinion.
your post is confusing, you obviously refer to this Vertex paper
Journal of Medicinal Chemistry, 2014;57(8):3382-3400.
which describes a classical medicinal chemistry effort, which has no relation to stem cell therapy
HPS alpha/beta selective inhibitor has been identified and published as a drug target for Huntington disease and VRTX has "compound 31"in works that crosses the blood brain barrier and decreases Htt level in brain. Data in mouse published in Nature chemistry magazine 4/2014. J L said Huntington disease was VRTX next target after CF and VRTX was not interested in spending $$ on VX 509 in Jan 2014.
It amazes me to see a small molecule developer like VRTX has so much future investments and moves in Stem cell therapies when all the initial stem cell companies failed to bring any product to the market.
Epix Pharmaceuticals-As of July 2009, the company was in the process of asset liquidation due to insufficient funds to stay afloat.
Tolerx-In 2008, Tolerx was named one of Fierce Biotech’s Fierce 15. In October 2011, Tolerx was shut down due to an unsuccessful Phase III trial in patients recently diagnosed with Type 1 diabetes.
Talk about a reversal of fortunes.
Three years after being heralded as the fastest drug launch ever and quickly racking up $1 billion in sales, the Incivek hepatitis C treatment will be discontinued this coming October by Vertex Pharmaceuticals..................do your research. These are the same people that brought you Epix and Tolerx. Make their money from selling shares not curing diseases. Please not another tirade from some bleeding heart that says I need to buy shares and BELIEVE in the "project". Business whatever it may be NEEDS to make profits. TY n GL!
Sentiment: Strong Sell
Analysts give value to assets looking positive going into phase 3 trials, and call the results of phase 3 trials 'binary events' while earlier phase assets get essentially no value (except perhaps when the brokerage is doing investment banking for the company). Vertex execs understand analysts can only focus on the CF pipeline since it is the closest to market, and will value the company based on it's progress in CF until earlier phase assets progress positively and approach Phase 3 clinical trials as well. Thus the emphasis on the CF pipeline almost exclusively during conference calls, but remember many of the 1800 employees at Vertex are scientists working on the preclinical optimization of drugs that will be financed in clinical trials from the revenue from 809/770 including next generation correctors for CF and the further development of the non CF pipeline described in the most recent 10Q,
"The most recent Form 10-Q mentions pipeline including oncology, MS, and flu drug VX-787 and its backup VX-353. "
That is good. However, most people do not read the 10-Q reports. Jeff or the medical/scientific officers should mention the compounds in the pipeline and elaborate with some details during their presentation. I understand that they want to end the conference call within one hour and that may may the reason they limit their presentation mostly to CF. It seems to me they should not mind stretching the call a bit longer than one hour and cover the pipeline.
The most recent Form 10-Q mentions pipeline including oncology, MS, and flu drug VX-787 and its backup VX-353. 10-Q also states that the IVA+LUM combo addressable group is greater than 22K excluding young people of 11 year old or younger.
I speculate that the reason they don't mention VX-765 in relation to AIDS is that they want to make sure that it works in alive human patients. The preclinical results are so good that it takes equally good clinical results to convert doubters. Also, they don't forget the demise of VX-222 and -135.
I posted similar complaint on this board a while ago.
Effective people are capable of being multitask. I am wondering if Jeff Leiden and his team are multitask types. All they talk about is CF, CF, CF. What about the pipeline Jeff? What happens when competition will come up with a better CF drug. We could go back to an annual loss just like when Incivek hit the dust!